Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 21Leukemia 9Gastrointestinal Stromal Tumors 4Philadelphia Chromosome 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid 3Bone Marrow Diseases 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myeloproliferative Disorders 2Hematologic Neoplasms 2Bronchiolitis Obliterans Syndrome 2Sarcoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Hematologic Diseases 1

Interventions

tofacitinib 7Imatinib Mesylate 5ibrutinib 3ofatumumab 2nilotinib 2ruxolitinib 1canakinumab 1bosutinib 1Sirolimus 1Rituximab 1Proto-Oncogene Proteins c-raf 1Photopheresis 1Pentostatin 1Mycophenolic Acid 1Methotrexate 1Infliximab 1Everolimus 1Etanercept 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Bronchiolitis Obliterans Syndrome × nilotinib × Clear all
NCT00802841 2015-11-16

LASOR

Novartis

Phase 3 Completed
191 enrolled 13 charts
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01819389 2014-01-07

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Hospital Universitario Dr. Jose E. Gonzalez

Phase 3 Completed
10 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡